Skip to main content

Table 2 Summary of findings and strength of evidence in studies

From: Efficacy and safety of bempedoic acid for prevention of cardiovascular events and diabetes: a systematic review and meta-analysis

Outcome No. of patients (Trials) RR/MD (95% CI) I2 Absolute effect estimates (per 1000) Quality of the evidence
Intervention Control Difference
Cardiovascular events 3008 (2) 0.75 [0.56, 0.99] 0% 56 74 − 19 [− 1, − 33] High
Percent change of LDL-C 3957 (9) − 22.91 [− 27.35, − 18.47] 99% Moderate#
New-onset or worsening diabetes 3621 (4) 0.65 [0.44, 0.96] 23% 38 58 − 20 [− 2, − 32] Moderate§
Percent change of CRP 3555 (7) − 24.70 [− 32.10, − 17.30] 53% Moderate#
Myocardial infarction 3008 (2) 0.54 [0.25, 1.15] 37% 12 22 − 10 [− 17, 3] Moderate§,#
Coronary revascularization 3008 (2) 0.74 [0.50, 1.10] 0% 29 39 − 10 [− 20, 4] Moderate§
Cardiovascular death 3008 (2) 1.65 [0.46, 5.98] 0% 5 3 2 [− 2, 15] Moderate§
Nonfatal stroke 3008 (2) 1.11 [0.34, 3.61] 0% 4 4 0 [− 3, 10] Moderate§
Hospitalization for unstable angina 2574 (2) 0.84 [0.41, 1.73] 51% 11 13 − 2[− 8, 9] Low#,§
Any adverse event 4188 (9) 1.01 [0.97, 1.05] 40% 712 705 7 [− 21, 35] Low&,#
Serious adverse event 4184 (9) 1.06 [0.89, 1.26] 0% 126 119 7 [− 13, 31] Moderate&
Muscular-related adverse event 2703 (3) 1.12 [0.80, 1.56] 26% 120 107 13 [− 21, 60] Moderate§
Decrease in glomerular filtration rate 3276 (3) 3.61 [0.81, 16.04] 0% 4 1 3 [− 1, 14] Low*
Increase in blood creatinine 3482 (4) 2.15[0.81, 5.69] 0% 6 3 3 [− 1, 16] Moderate§
Increase in blood uric acid 1176 (3) 3.76 [1.24, 11.39] 0% 30 8 22 [2,81] Low*
Gout 3421 (4) 2.37 [0.88, 6.36] 12% 12 5 7 [− 1, 43] Moderate§
Neurocognitive disorders 3076 (3) 0.94 [0.41, 2.17] 0% 8 8 0 [− 5, 9] Moderate§
ALT or AST > 3 × ULN 3382 (5) 1.97 [0.61, 6.34] 0% 6 3 3 [− 1, 14] Moderate§
CK > 5 × ULN 3382 (5) 1.31 [0.23, 7.50] 19% 3 2 1 [− 1, 12] Moderate§
  1. LDL-C Low density lipoprotein cholesterol, CRP C-reactive protein, CK Creatine kinase, ALT Alanine aminotransferase, AST Aspartate aminotransferase, ULN Upper limit of the normal range, RR Risk ratio, MD Mean difference
  2. &Publication bias
  3. #Inconsistency
  4. §Imprecision
  5. *Very serious imprecision